Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Current Liabilities (2016 - 2025)

UroGen Pharma (URGN) has disclosed Total Current Liabilities for 10 consecutive years, with $46.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.02% year-over-year to $46.4 million, compared with a TTM value of $46.4 million through Dec 2025, up 1.02%, and an annual FY2025 reading of $46.4 million, up 1.02% over the prior year.
  • Total Current Liabilities was $46.4 million for Q4 2025 at UroGen Pharma, up from $42.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $47.5 million in Q2 2025 and bottomed at $17.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $29.2 million, with a median of $26.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities dropped 5.33% in 2022, then surged 59.45% in 2025.
  • Year by year, Total Current Liabilities stood at $22.4 million in 2021, then increased by 6.86% to $23.9 million in 2022, then soared by 30.51% to $31.2 million in 2023, then skyrocketed by 47.22% to $45.9 million in 2024, then grew by 1.02% to $46.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for URGN at $46.4 million in Q4 2025, $42.2 million in Q3 2025, and $47.5 million in Q2 2025.